source
- Endeavor BioMedicines reports mid-stage trial success for IPF drug, suggests disease reversal potentialEndeavor BioMedicines announced that its experimental therapy for idiopathic pulmonary fibrosis has met its primary goals in a Phase 2 study. The company said the mid‑stage trial showed signs that…
- FDA extends safety review of mifepristone into next year, report due by March 2027The FDA announced that its ongoing safety evaluation of mifepristone, the primary medication used for medical abortions, will not be completed until next year. The agency expects to finish the saf…